

Global Respiratory Drugs Market 2018-2024

<https://marketpublishers.com/r/G94DE0B6AA7EN.html>

Date: March 2018

Pages: 113

Price: US\$ 2,750.00 (Single User License)

ID: G94DE0B6AA7EN

Abstracts

Respiratory disorders, which affect mechanisms of the respiratory system such as the lungs and airway, are a wide-ranging chronic disease with a diversity of underlying causes, ranging from inherited mutations to pathological inflammation. The respiratory disorders market is dominated by long-acting beta-agonist (LABA) and long-acting muscarinic antagonist (LAMA) therapies for chronic obstructive pulmonary disease (COPD) and asthma. These drugs stimulate muscles surrounding the bronchial tubes to suppress and open the airways.

Respiratory therapy area consists of signs that affect the lungs, bronchi, trachea, larynx, pharynx and nose in various ways, such as the scarring of lung tissue or the extreme production of mucus. Respiratory disease generally results in breathing difficulties, that can lead to troubles in sleep, wheezing, anxiety, and stress. During worse condition, shortness of breath (dyspnea) can limit physical activity, affecting both the quality of life and life expectancy of sufferers. The cause of respiratory disorders contrasts significantly across each indication and comprises factors such as environment, occupation, genetic predisposition, and aging.

Report Scope:

Report Category: Pharmaceuticals / Healthcare

Therapy Type

Asthma

Chronic Obstructive Pulmonary Disease

Idiopathic Pulmonary Fibrosis

Cystic Fibrosis

End-user

Hospitals
Ambulatory Care
Others

Regions

North America
Europe
Asia Pacific
Rest of the World

Industry Outlook: Market Trends and Drivers, Restraints, and Opportunities

Contents

1 INDUSTRY OUTLOOK

- 1.1 Industry Overview
- 1.2 Total Addressable Market
- 1.3 Industry Trends

2 REPORT OUTLINE

- 2.1 Report Scope
- 2.2 Report Summary
- 2.3 Research Methodology
- 2.4 Report Assumptions

3 MARKET SNAPSHOT

- 3.1 Market Definition – Infoholic Research
- 3.2 Segmented Addressable Market (SAM)
- 3.3 Importance of Respiratory Care
- 3.4 Trends of Respiratory Drugs Market
- 3.5 Related Markets
 - 3.5.1 Oncology (Cancer) Drugs
 - 3.5.2 Active pharmaceutical ingredients (APIs)
 - 3.5.3 Over the counter drugs (OTC)
 - 3.5.4 Diabetes Drugs

4 MARKET OUTLINE

- 4.1 Pipeline Products of Respiratory Drugs by Major Companies
- 4.2 Market Segmentation
- 4.3 Porter 5(Five) Forces
- 4.4 PEST Analysis

5 MARKET CHARACTERISTICS

- 5.1 Market Dynamics of Respiratory Drugs Market
 - 5.1.1 Drivers
 - 5.1.1.1 Increasing Aging Population

- 5.1.1.2 Rising prevalence of respiratory diseases
- 5.1.1.3 High prevalence of tobacco smoking
- 5.1.2 Opportunities
 - 5.1.2.1 Supportive initiatives from government and other organizations
 - 5.1.2.2 Huge pool of undiagnosed chronic obstructive pulmonary disease population
- 5.1.3 Restraints
 - 5.1.3.1 Expiry of patents for blockbuster drugs
 - 5.1.3.2 Complex drug development process
- 5.1.4 DRO – Impact Analysis
- 5.1.5 Key Stakeholders

6 APPLICATION: MARKET SIZE AND ANALYSIS

- 6.1 Overview
- 6.2 Asthma
- 6.3 Chronic Obstructive Pulmonary Disease (COPD)
- 6.4 Cystic Fibrosis
- 6.5 Allergic Rhinitis
- 6.6 Others

7 REGIONS: MARKET SIZE AND ANALYSIS

- 7.1 Overview
- 7.2 North America
 - 7.2.1 Overview
 - 7.2.2 United States
 - 7.2.3 Canada
- 7.3 Europe
 - 7.3.1 Overview
 - 7.3.2 United Kingdom
 - 7.3.3 Germany
 - 7.3.4 France
- 7.4 APAC
 - 7.4.1 Overview
 - 7.4.2 India
 - 7.4.3 China
 - 7.4.4 Japan
- 7.5 Rest of the World
 - 7.5.1 Overview

7.5.2 Middle East

7.5.3 Brazil

7.5.4 Mexico

8 COMPETITIVE LANDSCAPE

9 VENDOR PROFILES

9.1 Novartis AG

9.1.1 Overview

9.1.2 Business Unit

9.1.3 Geographic Presence

9.1.4 Business Focus

9.1.5 SWOT Analysis

9.1.6 Business Strategy

9.2 GlaxoSmithKline plc

9.2.1 Overview

9.2.2 Geographic Presence

9.2.3 Business Focus

9.2.4 SWOT Analysis

9.2.5 Business Strategy

9.3 Astra Zenca PLC

9.3.1 Overview

9.3.2 Geographic Presence

9.3.3 Business Focus

9.3.4 SWOT Analysis

9.3.5 Business Strategy

9.4 F.Hoffmann-La Roche Ltd.

9.4.1 Overview

9.4.2 Business Unit

9.4.3 Geographic Presence

9.4.4 Business Focus

9.4.5 SWOT Analysis

9.4.6 Business Strategy

9.5 Vertex Pharmaceuticals Inc.

9.5.1 Overview

9.5.2 Geographic Presence

9.5.3 Business Focus

9.5.4 SWOT Analysis

9.5.5 Business Strategy

10 COMPANIES TO WATCH FOR

10.1 Boehringer Ingelheim GmbH

10.1.1 Overview

10.1.2 Highlights

10.2 Teva Pharmaceutical Industries Ltd.

10.2.1 Overview

10.2.2 Highlights:

10.3 Gilead Sciences Inc.

10.3.1 Overview

10.3.2 Highlights:

10.4 Bayer AG

10.4.1 Overview

10.5 Pfizer Inc.

10.5.1 Overview

10.5.2 Highlights

10.6 Bristol-Myers Squibb Co.

10.6.1 Overview

10.7 Merck & Co.

10.7.1 Overview

10.7.2 Highlights:

10.8 Sanofi

10.8.1 Overview

10.9 Mallinckrodt plc

10.9.1 Overview

Annexure

Abbreviations

?

Tables

Table 1 RESPIRATORY DRUGS: PIPELINE PRODUCTS

Table 2 PATENT EXPIRATION OF RESPIRATORY DRUGS

Table 3 RESPIRATORY DRUGS MARKET REVENUE BY APPLICATION, 2017–2024
(\$MILLION)

Table 4 RESPIRATORY DRUGS MARKET REVENUE BY REGIONS, 2017–2024

(\$MILLION)

Table 5 MAJOR RESPIRATORY DRUGS MARKET (\$MILLION)

Table 6 NOVARTIS AG: OFFERINGS

Table 7 NOVARTIS AG: RECENT DEVELOPMENTS

Table 8 NOVARTIS AG RESPIRATORY DRUGS PIPELINE MOLECULES

Table 9 GLAXOSMITHKLINE PLC: OFFERINGS

Table 10 GLAXOSMITHKLINE PLC: RECENT DEVELOPMENTS

Table 11 ASTRA ZENCA PLC: OFFERINGS

Table 12 ASTRA ZENCA PLC: RECENT DEVELOPMENTS

Table 13 F. HOFFMANN-LA ROCHE LTD.: OFFERINGS

Table 14 F. HOFFMANN-LA ROCHE LTD.: RECENT DEVELOPMENTS

Table 15 ROCHE: PIPELINE MOLECULES IN RESPIRATORY DRUGS SEGMENT

Table 16 VERTEX PHARMACEUTICALS INC.: OFFERINGS

Table 17 VERTEX PHARMACEUTICALS INC.: RECENT DEVELOPMENTS

Table 18 VERTEX PHARMACEUTICALS: PIPELINE MOLECULES IN RESPIRATORY DRUGS SEGMENT

Table 19 BOEHRINGER INGELHEIM GMBH: OVERVIEW

Table 20 TEVA PHARMACEUTICAL INDUSTRIES LTD.: OVERVIEW

Table 21 GILEAD SCIENCES INC.: OVERVIEW

Table 22 BAYER AG: OVERVIEW

Table 23 BAYER AG: RECENT DEVELOPMENTS

Table 24 PFIZER INC. OVERVIEW

Table 25 PFIZER INC.: RECENT DEVELOPMENTS

Table 26 BRISTOL-MYERS SQUIBB CO.: OVERVIEW

Table 27 BRISTOL-MYERS SQUIBB CO.: KEY DEVELOPMENTS

Table 28 MERCK & CO.: OVERVIEW

Table 29 MERCK & CO.: RECENT DEVELOPMENTS

Table 30 SANOFI: OVERVIEW

Table 31 SANOFI: RECENT DEVELOPMENTS

Table 32 MALLINCKRODT PLC: OVERVIEW

Charts

Chart 1 RESEARCH METHODOLOGY OF GLOBAL RESPIRATORY DRUGS MARKET

Chart 2 GLOBAL RESPIRATORY DRUGS MARKET REVENUE, 2017-2024 (\$MILLION)

Chart 3 SEGMENTATION OF GLOBAL REPIRATORY DRUGS MARKET

Chart 4 PORTER 5 FORCES OF RESPIRATORY DRUGS MARKET

Chart 5 PEST ANALYSIS OF REPIRATORY DRUGS MARKET

Chart 6 MARKET DYNAMICS – DRO ANALYSIS

Chart 7 WORLD POPULATION AGED 65 YEARS AND ABOVE, 1960-2060 (%)

Chart 8 DRO – IMPACT ANALYSIS OF GLOBAL RESPIRATORY DRUGS MARKET

Chart 9 KEY STAKEHOLDERS

Chart 10 RESPIRATORY DRUGS MARKET BY APPLICATION SEGMENTATION, 2017 VS 2024 (%)

Chart 11 RESPIRATORY DRUGS MARKET REVENUE IN ASTHMA APPLICATION, 2017-2024 (\$MILLION)

Chart 12 RESPIRATORY DRUGS MARKET REVENUE IN COPD APPLICATION, 2017-2024 (\$MILLION)

Chart 13 RESPIRATORY DRUGS MARKET REVENUE IN CYSTIC FIBROSIS APPLICATION, 2017-2024 (\$MILLION)

Chart 14 RESPIRATORY DRUGS MARKET REVENUE IN ALLERGIC RHINITIS APPLICATION, 2017-2024 (\$MILLION)

Chart 15 RESPIRATORY DRUGS MARKET REVENUE IN OTHERS APPLICATION, 2017-2024 (\$MILLION)

Chart 16 RESPIRATORY DRUGS MARKET BY REGIONAL SEGMENTATION, 2017 VS 2024 (%)

Chart 17 RESPIRATORY DRUGS MARKET REVENUE IN NORTH AMERICA, 2017-2024 (\$MILLION)

Chart 18 RESPIRATORY DRUG MARKET REVENUE IN THE EUROPE REGION, 2017–2023 (\$MILLION)

Chart 19 RESPIRATORY DRUGS MARKET REVENUE IN THE APAC REGION, 2017-2024 (\$MILLION)

Chart 20 RESPIRATORY DRUGS MARKET REVENUE IN REST OF THE WORLD, 2017–2024 (\$MILLION)

Chart 21 RESPIRATORY PIPELINE DRUGS IN THE MARKET

Chart 22 MARKET SHARE OF MAJOR PLAYERS-2017 (%)

Chart 23 NOVARTIS AG: OVERVIEW SNAPSHOT

Chart 24 NOVARTIS AG: BUSINESS UNITS

Chart 25 NOVARTIS AG: GEOGRAPHICAL PRESENCE

Chart 26 NOVARTIS AG: SWOT ANALYSIS

Chart 27 GLAXOSMITHKLINE PLC: OVERVIEW SNAPSHOT

Chart 28 GLAXOSMITHKLINE PLC: BUSINESS UNITS

Chart 29 GLAXOSMITHKLINE PLC: GEOGRAPHIC PRESENCE

Chart 30 GSK: REVENUE OF RESPIRATORY PORTFOLIO

Chart 31 GLAXOSMITHKLINE PLC: SWOT ANALYSIS

Chart 32 ASTRA ZENCA PLC: OVERVIEW SNAPSHOT

Chart 33 ASTRA ZENCA PLC: BUSINESS UNITS

Chart 34 ASTRA ZENCA PLC: GEOGRAPHIC PRESENCE

Chart 35 ASTRA ZENCA PLC: SWOT ANALYSIS

Chart 36 F. HOFFMANN-LA ROCHE LTD.: OVERVIEW SNAPSHOT

Chart 37 F. HOFFMANN.LA ROCHE LTD.: BUSINESS UNITS

Chart 38 F. HOFFMANN-LA ROCHE: GEOGRAPHICAL PRESENCE

Chart 39 F. HOFFMANN-LA ROCHE LTD.: SWOT ANALYSIS

Chart 40 VERTEX PHARMACEUTICALS INC.: OVERVIEW SNAPSHOT

Chart 41 VERTEX PHARMACEUTICALS INC.: GEOGRAPHICAL PRESENCE

Chart 42 VERTEX PHARMACEUTICALS INC.: SWOT ANALYSIS

I would like to order

Product name: Global Respiratory Drugs Market 2018-2024

Product link: <https://marketpublishers.com/r/G94DE0B6AA7EN.html>

Price: US\$ 2,750.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/G94DE0B6AA7EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970